Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6690021.pdf
Reference35 articles.
1. Abrams, J. S., Roncarolo, M. G., Yssel, H., Andersson, U., Gleich, G. J. & Silver, J. E. (1992). Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127: 5–24.
2. Alleva, D. G., Askew, D., Burger, C. J. & Elgert, K. D. (1993). Tumor-induced macrophage Tumor Necrosis Factor-α production suppresses autoreactive T cells. Immunobiology 188: 430–435.
3. Bachwich, P. R., Chensue, S. W., Larrick, J. W. & Kunkel, S. L. (1986). Tumor necrosis factor α stimulates interleukin-1 and prostaglandin-E2 production in resting macrophages. Biochem Biophys Res Commun 136: 94–101.
4. Bain, C., Puisieux, I., Merrouche, Y., Duc, A., Colombo, M. P. & Favrot, M. C. (1996). B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 67: 769–776.
5. Benjamin, D., Knoblock, T. J. & Dayton, M. A. (1992). Human B cell interleukin-10: B cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma constitutively secrete large quantities of interleukin-10. Blood 80: 1289–1298.
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group;Frontiers in Oncology;2024-05-24
2. Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials;Cancers;2023-05-30
3. Lipids as Targets for Renal Cell Carcinoma Therapy;International Journal of Molecular Sciences;2023-02-07
4. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma;Journal of Cancer;2023
5. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma;Clinical Cancer Research;2022-07-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3